Global Cancer Biopsy Market Size By Type (Tissue Biopsies, Liquid Biopsies), By Application (Breast Cancer, Colorectal Cancer), By Region, And Segment Forecasts, 2023 to 2032

The Global Cancer Biopsy Market was valued at USD 28.3 billion in 2023 and is projected to surpass USD 54.7 billion by 2031, growing at a CAGR of 8.7% during the forecast period from 2023 to 2031. The market growth is fueled by the rising prevalence of cancer worldwide, increasing demand for minimally invasive diagnostic procedures, and continuous advancements in biopsy technologies. Cancer biopsies play a critical role in accurate diagnosis, staging, and monitoring of cancer, significantly influencing treatment outcomes. The adoption of liquid biopsies and image-guided biopsy techniques is further augmenting market expansion.

Drivers:

1. Increasing Cancer Incidence Globally:

The growing number of cancer cases, especially breast, lung, prostate, and colorectal cancers, is a primary factor propelling the demand for reliable diagnostic methods like biopsies.

2. Shift Towards Minimally Invasive Procedures:

Patient preference and clinical benefits associated with minimally invasive and non-invasive biopsy techniques such as fine-needle aspiration and liquid biopsy are accelerating market adoption.

3. Technological Advancements:

Innovations including digital pathology, AI-based biopsy imaging analysis, and next-generation sequencing (NGS) are enhancing the precision and efficiency of cancer diagnosis.

Restraints:

1. High Cost of Advanced Biopsy Techniques:

The cost-intensive nature of image-guided and molecular biopsy technologies limits their adoption in cost-sensitive and underdeveloped healthcare markets.

2. Risks and Complications Associated with Biopsies:

Potential complications such as bleeding, infection, and pain following invasive biopsies can deter patient compliance and restrict widespread application.

Opportunity:

1. Growing Adoption of Liquid Biopsy:

Liquid biopsy is emerging as a promising tool for early cancer detection, monitoring disease progression, and identifying recurrence with reduced patient discomfort.

2. Expansion of Diagnostic Infrastructure in Emerging Economies:

Countries across Asia-Pacific, Latin America, and Africa are investing in healthcare infrastructure, offering growth opportunities for biopsy equipment and service providers.

Market by System Type Insights:

In 2023, the Needle Biopsy segment dominated the market due to its widespread usage in diagnosing cancers of the breast, thyroid, and lungs. Its minimally invasive nature, lower cost, and high diagnostic accuracy contribute to its popularity. However, the Liquid Biopsy segment is projected to grow at the fastest rate during the forecast period, driven by its ability to detect circulating tumor DNA (ctDNA) with a simple blood sample.

Market by End-use Insights:

Hospitals accounted for the largest market share in 2023 due to their comprehensive diagnostic capabilities and availability of advanced imaging and biopsy equipment. Diagnostic Centers are anticipated to grow significantly as standalone facilities gain popularity for their speed, convenience, and affordability, especially in urban areas.

Market by Regional Insights:

North America led the global market in 2023, driven by high cancer prevalence, strong healthcare infrastructure, and the early adoption of advanced biopsy tools. Meanwhile, Asia-Pacific is projected to witness the highest growth rate due to increasing cancer screening programs, growing healthcare expenditure, and rising awareness in countries such as China, India, and South Korea.

Competitive Scenario:

Key players in the Global Cancer Biopsy Market include Qiagen N.V., Illumina Inc., Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Danaher Corporation, Guardant Health, Inc., Roche Diagnostics, Myriad Genetics, Inc., and Hologic, Inc. These companies are actively investing in R&D, launching innovative diagnostic tools, and engaging in strategic collaborations to enhance their market presence.

Scope of Work – Global Cancer Biopsy Market

Report Metric Details

Market Size (2023) USD 28.3 Billion

Projected Market Size (2031) USD 54.7 Billion

CAGR (2023–2031) 8.7%

Market Segments System Type (Needle Biopsy, Liquid Biopsy, Surgical Biopsy), End-use (Hospitals, Diagnostic Centers, Others)

Growth Drivers Rising cancer incidence, technological advancement, demand for minimally invasive diagnostics

Opportunities Liquid biopsy adoption, emerging market expansion

Key Market Developments:

2023: Illumina Inc. introduced a new high-sensitivity liquid biopsy assay for detecting early-stage cancers using next-generation sequencing.

2024: Roche Diagnostics expanded its oncology diagnostics division with a new AI-powered biopsy analysis tool to enhance diagnostic accuracy.

2025: Guardant Health partnered with major U.S. healthcare providers to scale up the deployment of its ctDNA-based liquid biopsy platform